We develop next-generation Pb-212 targeted alpha radiopharmaceuticals designed to selectively destroy cancer cells with unmatched precision. By combining deep expertise in Pb-212 chemistry, innovative chelation technologies, and a growing pipeline of best-in-class programs, we are shaping the future of targeted alpha therapy.
A key differentiator is our unique patent covering the use of a broad range of targeting molecules—antibodies, peptides, small molecules, and kinase inhibitors—in combination with Pb-212. This proprietary platform enables versatile, highly stable radiopharmaceuticals that can address both solid and hematologic tumors.
We are building a fully integrated radiopharmaceutical company with Pb-212 at its core. As radiopharmaceutical therapy continues to transform oncology, Pb-212 offers powerful advantages: potent single-alpha emissions, minimal off-target toxicity, and seamless theranostic pairing for personalized treatment.
Our mission is clear: deliver precise, effective Pb-212 therapies that improve outcomes for patients with cancer.